Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-...
August 24, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
MaxCyte Announces a Business & Technical Update at Biotech Showcase 2013
January 4, 2013
Gaithersburg, Maryland - MaxCyte, Inc., the pioneer in scalable, high performance transient transfection systems, announces that Mr. Douglas Doerfler, President & CEO of MaxCyte, will present a business and technical update during Biotech Showcase 2013 to be held at the Parc 55 Wyndham San Francisco - Union Square in San Francisco, CA. Mr. Doerfler will speak on Tuesday, January 8, 2013, at 10:00 AM PST, in Track B held in Room Mission I. MaxCyte management will be available during the conference for detailed discussions in one-on-one meetings.
MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. MaxCyte's portfolio of instrumentsincludes the MaxCyte GT® Flow Transfection System for autologous and allogeneic cellular therapies,and the MaxCyte STX® Scalable Transfection System and the MaxCyte VLX® Large Scale Transfection System for drug discovery research, screening, and protein production. The MaxCyte Transfection Systems rapidly and consistently transfect primary cells, stem cells, and cell lines with a broad range of molecules at volumes from the bench to manufacturing scale in less than 30 minutes for research, production, clinical applications, and point of care use.
About Biotech Showcase™ 2013
Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week which is widely viewed as setting the tone for the coming year. Now in its fifth year, Biotech Showcase is expected to attract upwards of 1,500 attendees. The program includes lunch plenary sessions featuring top industry leaders and innovators speaking on industry -and time-relevant topics, as well as presentations from both private and public companies.